STATISTICAL CONSIDERATIONS IN MONITORING THE SYSTOLIC HYPERTENSION IN THE ELDERLY PROGRAM (SHEP)

被引:11
作者
DAVIS, BR
WITTES, J
PRESSEL, S
BERGE, KG
HAWKINS, CM
LAKATOS, E
MOYE, LA
PROBSTFIELD, JL
机构
[1] STAT COLLABORAT,WASHINGTON,DC
[2] MAYO CLIN & MAYO GRAD SCH MED,MAYO CLIN,ROCHESTER,MN 55901
[3] GH BESSELAAR ASSOCIATES,PRINCETON,NJ
[4] FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104
来源
CONTROLLED CLINICAL TRIALS | 1993年 / 14卷 / 05期
关键词
DATA MONITORING; STOCHASTIC CURTAILMENT; CONDITIONAL POWER; LAG TIME;
D O I
10.1016/0197-2456(93)90051-E
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Systolic Hypertension in the Elderly Program (SHEP), a randomized, double-masked, placebo-controlled trial of 4736 persons, was designed to assess the efficacy of antihypertensive drug treatment to reduce the risk of fatal and nonfatal strokes among people age 60 and over with isolated systolic hypertension. The statistical method used in interim monitoring of results was conditional power (or stochastic curtailment). The findings did not become conclusive until near the completion of the trial, and therefore SHEP was continued to its scheduled closing date. The trial demonstrated a 36% reduction in the incidence of stroke in the active treatment group (P = .0003). In addition to evaluating overall efficacy of treatment, the monitoring process considered such other issues as nonstroke outcomes, lag time between first report of stroke and final confirmation of stroke diagnosis, consistency of results across subgroups, and completeness of follow-up. The purpose of this article is to review these factors with primary emphasis on the statistical aspects.
引用
收藏
页码:350 / 361
页数:12
相关论文
共 21 条
[1]   REPEATED SIGNIFICANCE TESTS ON ACCUMULATING DATA [J].
ARMITAGE, P ;
MCPHERSO.CK ;
ROWE, BC .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-GENERAL, 1969, 132 :235-&
[2]   TERMINATION OF CLINICAL-TRIALS - THE BETA-BLOCKER HEART ATTACK TRIAL AND THE HYPERTENSION DETECTION AND FOLLOW-UP PROGRAM EXPERIENCE [J].
BELL, RL ;
CURB, JD ;
FRIEDMAN, LM ;
PAYNE, GH .
CONTROLLED CLINICAL TRIALS, 1985, 6 (02) :102-111
[3]   MONITORING A RANDOMIZED CLINICAL-TRIAL FOR FUTILITY - THE NORTH-NORWEGIAN LIDOCAINE INTERVENTION TRIAL [J].
BERNTSEN, RF ;
RASMUSSEN, K ;
BJORNSTAD, JF .
STATISTICS IN MEDICINE, 1991, 10 (03) :405-412
[4]   RATIONALE AND DESIGN [J].
BORHANI, NO ;
APPLEGATE, WB ;
CUTLER, JA ;
DAVIS, BR ;
FURBERG, CD ;
LAKATOS, E ;
PAGE, L ;
PERRY, HM ;
SMITH, WM ;
PROBSTFIELD, JL .
HYPERTENSION, 1991, 17 (03) :2-15
[5]  
Cairns J, 1991, Ann Epidemiol, V1, P395
[6]   REPEATED CONFIDENCE-INTERVALS AND PREDICTION INTERVALS USING STOCHASTIC CURTAILMENT [J].
DAVIS, BR ;
HARDY, RJ .
COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1992, 21 (02) :351-368
[7]   UPPER-BOUNDS FOR TYPE-I AND TYPE-II ERROR RATES IN CONDITIONAL POWER CALCULATIONS [J].
DAVIS, BR ;
HARDY, RJ .
COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1990, 19 (10) :3571-3584
[8]   STATISTICAL ASPECTS OF EARLY TERMINATION IN THE BETA-BLOCKER HEART ATTACK TRIAL [J].
DEMETS, DL ;
HARDY, R ;
FRIEDMAN, LM ;
LAN, KKG .
CONTROLLED CLINICAL TRIALS, 1984, 5 (04) :362-372
[9]   ASSESSING POSSIBLE LATE TREATMENT EFFECTS IN STOPPING A CLINICAL-TRIAL EARLY - A CASE-STUDY - DIABETIC-RETINOPATHY STUDY REPORT NO 9 [J].
EDERER, F ;
PODGOR, MJ .
CONTROLLED CLINICAL TRIALS, 1984, 5 (04) :373-381
[10]   AN AID TO DATA MONITORING IN LONG-TERM CLINICAL-TRIALS [J].
HALPERIN, M ;
LAN, KKG ;
WARE, JH ;
JOHNSON, NJ ;
DEMETS, DL .
CONTROLLED CLINICAL TRIALS, 1982, 3 (04) :311-323